The Acquired Resistance to Therapy Network (ARTNet), of @theNCI focuses on mechanisms of acquired resistance to cancer therapies & disease recurrence and integrates those findings through team science. Learn more at nciartnet.org and t.ly/ZbxF3

At today's #ARTNetSCMeeting, Dr. Alan Hutson @Amherst73 of @RoswellPark provided network updates, followed by a presentation from Dr. Vlad Sandulache of @bcmhouston on modeling tumor–tumor immune microenvironment (TIME) interactions across time and space in head and neck squamous cell carcinoma (HNSCC).

New research identifies TNIK as a potential driver of chemoradiation resistance in limited-stage small cell lung cancer (SCLC). Using patient-derived models, investigators found that TNIK overexpression promotes resistance, while genetic or pharmacologic TNIK inhibition enhanced sensitivity to chemoradiation—potentially by impairing the DNA damage response. The findings highlight TNIK as a promising therapeutic target to improve response to standard chemoradiotherapy in SCLC. 🔗 pubmed.ncbi.nlm.nih.gov/4183… #ARTNetPublication #SCLC #LungCancer #CancerResearch #RadiationOncology #PrecisionOncology

📢 2026 AAADV Workshop | Nov. 5–6 Join leaders in oncology drug development for discussions on regulatory science, multiregional clinical trials, dose optimization, immuno-oncology toxicity, and more. 📍 Bethesda, MD + Virtual 🔗 Register: eventzilla.net/e/2026aaadvwo… #CancerResearch #Oncology #DrugDevelopment #ClinicalTrials

At today’s #ARTNetSCMeeting, SC Co-Chair Dr. Alan Hutson @Amherst73 of @RoswellPark shared network updates. Dr. Liron Bar-Peled @LironBarPeled of @MGHCancerCenter and @harvardmed gave a fascinating talk on “Identification of Druggable and Redox Vulnerabilities in Cancer.”

At today's Inflammatory Microenvironment and Tumor Cross-Talk #ARTNetWG meeting, Dr. Samuel McBrayer fo @CRI_UTSW presented on Metabolite Signaling in the Glioma Microenvironment.

A fascinating episode and well worth your time! #ARTNetPodcast Episode 2: theartnetpodcast.riverside.c… In this episode, Dr. David Goodrich of @RoswellPark speaks with Dr. @VSandulache2025 of @bcmhouston about emerging research showing that many tumors may already be biologically primed to resist therapy before treatment even starts. Together, they explore how oxidative stress, metabolism, immune interactions, and environmental exposures shape tumor behavior, discuss the role of the NRF2 pathway in treatment resistance, and examine how these insights could lead to better biomarkers and more personalized treatment strategies for patients with head and neck cancer.

📢 Save the date! Join @theNCI Office of Data Sharing (ODS) Join Fourth Annual Symposium, Data to Discovery: Leveraging Cancer Data in the "Real World," on Nov. 5-6, 2026 in Rockville, MD. Submit a poster or demo abstract by Sept. 1 (travel award eligibility deadline: Aug. 3). Help advance cancer research through data sharing! events.cancer.gov/ods/annual… #CancerResearch #DataSharing #FAIRData